There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Danaher (DHR – Research Report) and ProSomnus (OSA – Research Report) with bullish sentiments.
Danaher (DHR)
Bernstein analyst Brendan Luecke maintained a Buy rating on Danaher today and set a price target of $300.00. The company’s shares closed last Monday at $255.75.
According to TipRanks.com, Luecke is ranked #4617 out of 8377 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $302.58 average price target, which is a 20.0% upside from current levels. In a report issued on April 4, Barclays also maintained a Buy rating on the stock with a $270.00 price target.
See today’s best-performing stocks on TipRanks >>
ProSomnus (OSA)
In a report released today, Scott Henry from Roth MKM initiated coverage with a Buy rating on ProSomnus and a price target of $9.00. The company’s shares closed last Friday at $5.17, close to its 52-week low of $4.57.
According to TipRanks.com, Henry is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ProSomnus with a $9.00 average price target, a 74.2% upside from current levels. In a report issued on April 3, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DHR:
- Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
- Danaher price target lowered to $270 from $290 at Barclays
- 5 Best Healthcare Stocks to Invest in Now, According to Analysts
- Citi puts ‘positive catalyst watches’ on three life science stocks
- Danaher partners with University of Pennsylvania on cell therapy innovation
